Neurological complications of biologic therapy in psoriasis: A review

Journal of Clinical and Aesthetic Dermatology

Volumn 2, Issue 11, 2009, Pages 28-33

  Bechtel, Mark ^a   Sanders, Catherine ^a   Bechtel, Ann ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; EFALIZUMAB; ETANERCEPT; IMMUNOGLOBULIN G; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB; VIRUS DNA;

ARTICLE; BIOLOGICAL THERAPY; CEREBROSPINAL FLUID ANALYSIS; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL FEATURE; CONFUSION; DEMYELINATING DISEASE; DERMATOLOGY; DISEASE ASSOCIATION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; GUILLAIN BARRE SYNDROME; HEALTH CARE PERSONNEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; JC VIRUS; LEUKOENCEPHALOPATHY; MULTIPLE SCLEROSIS; MYELITIS; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; POLYMERASE CHAIN REACTION; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS VULGARIS; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SEIZURE; VISUAL DISORDER;

EID: 77954302532     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Roos KL, Tyler KL. Meningitis, encephalitis, brain abscess, and empyema. In: Fauci AS, Braunwald E, Kasper DL, et al, eds. Harrison's Principles of Internal Medicine. 17th ed. Volumes I and II. New York: The McGraw-Hill Companies, Inc.; 2008:2634-2635.
2. Weber T. Progressive multifocal leukoencephalopathy. Neurol Clin. 2008;26(3):833-854.
3. Berenguer J, Miralles P, Arrizabalaga J, et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis. 2003;36(8): 1047-1052. Epub 2003 Apr 2.
4. Lima MA, Drislane FW, Koralnik, IJ. Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology. 2006;66(2):262-264.
5. Von Giesen HJ, Neuen-Jacob E, Dörries K, et al. Diagnostic criteria and clinical procedures in HIV-1 associated progressive multifocal leukoencephalopathy. J Neurol Sci. 1997;147(1):63-72.
6. Raptiva (PML 3rd Case) Dear Healthcare Provider letter; 2/2009. http://www.gene.com/gene/products/information/immunological/raptiva. Accessed on October 28, 2009.
7. Raptiva (PML) Dear Healthcare Provider letter; 10/2008. http://www.gene.com/gene/products/information/immunological/raptiva. Accessed on October 28, 2009.
8. Raptiva (PML 2nd Case) Dear Healthcare Provider letter; 11/2008. http://www.gene.com/gene/products/information/immunological/raptiva. Accessed on October 28, 2009.
9. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood. 2009;113(20):4834-4840. Pre-published online as a Blood First Edition Paper on March 5, 2009. (Epub ahead of print.)
10. Yamamoto M, Takahashi H, Wakasugi H, et al. Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis. Mod Rheumatol. 2007;17(1):72-74. Epub 2007 Feb 20.
11. Neff RT, Hurst FP, Falta EM, et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation. 2008; 86(10):1474-1478.
12. Stelara (ustekinumab) [package insert]. Malverna, PA: Centocor, Inc.
13. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006; 354(9):924-933.
14. Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med. 1989;170(2):607-612.
15. Van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996;47(6):1531-1534.
16. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor-a antagonism: by what mechanisms could tumor necrosis factor-a antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum. 2001;44(9):1977-1983.
17. Ruiz-Jimeno T, Carvajal A, Mata C, Aurrecoechea E. Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis treated with infliximab. J Rheumatol. 2006;33(7):1457-1458.
18. Hier DB. Demyelinating diseases. In: Samuels MA, ed. Manual of Neurologic Therapeutics. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:321.
19. Zivadinov R, Bakshi R. Optic neuritis: pathogenesis, immunology, diagnosis, and clinical management. In: Minagar A, Alexander JS, eds. Inflammatory Disorders of the Nervous System: Pathogenesis, Immunology, and Clinical Management. Totowa, NJ: Human Press Inc.; 2005:238.
20. Horton JC. Disorders of the eye. In: Fauci AS, Braunwald E, Kasper DL, et al, eds. Harrison's Principles of Internal Medicine. 17th ed. Volumes I and II. New York: The McGraw-Hill Companies, Inc.; 2008:187.
21. Adams AC. Mayo Clinic Essential Neurology. Rochester, MN: Mayo Clinic Scientific Press; 2008:152-154,322, 324-325,336.
22. Simsek I, Erdem H, Pay S, et al. Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2007;66(9):1255-1258.
23. Tran TH, Milea D, Cassoux N, et al. Optic neuritis associated with infliximab. J Fr Ophtalmol. 2005;28(2): 201-204.
24. Tauber T, Daniel D, Barash J, et al. Optic neuritis associated with etanercept therapy in two patients with extended oligoarticular juvenile idiopathic arthritis. Rheumatology (Oxford). 2005;44(3):405. Epub 2005 Jan 6.
25. Noguera-Pons R, Borrás-Blasco J, Romero-Crespo I, et al. Optic neuritis with concurrent etanercept and isoniazid therapy. Ann Pharmacother. 2005;39(12):2131-2135. Epub 2005 Nov 1.
26. Chung JH, Van Stavern GP, Frohman LP, Turbin RE. Adalimumab-associated optic neuritis. J Neurol Sci. 2006;244(1-2):133-136. Epub 2006 Mar 9.
27. Hauser SL, Goodin DS. Multiple sclerosis and other demyelinating diseases. In: Fauci AS, Braunwald E, Kasper DL, et al, eds. Harrison's Principles of Internal Medicine. 17th ed. Volumes I and II. New York: The McGraw-Hill Companies, Inc.; 2008:2611-2614.
28. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology. 2001;57(10): 1885-1888.
29. Enayati PJ, Papadakis KA. Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol. 2005;39(4):303-306.
30. Al Saieg N, Luzar MJ. Etanercept induced multiple sclerosis and transverse myelitis. J Rheumatol. 2006;33(6): 1202-1204.
31. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001; 44(12):2862-2869.
32. Bensouda-Grimaldi L, Mulleman D, Valat JP, Autret-Leca E. Adalimumab-associated multiple sclerosis. J Rheumatol. 2007;34(1):239-240.
33. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-127.
34. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002;59(4):499-505.
35. Hauser SL, Ropper AH. Diseases of the spinal cord. In: Fauci AS, Braunwald E, Kasper DL, et al, eds. Harrison's Principles of Internal Medicine. 17th ed. Volumes I and II. New York: The McGraw-Hill Companies, Inc.; 2008:2592-2593.
36. Hammerstedt HS, Edlow JA, Cusick S. Emergency department presentations of transverse myelitis: two case reports. Ann Emerg Med. 2005;46(3):256-259.
37. Sellner J, Lüthi N, Schüpbach WM, et al. Diagnostic workup of patients with acute transverse myelitis: spectrum of clinical presentation, neuroimaging, and laboratory findings. Spinal Cord. 2009;47(4):312-317. Epub 2008 Nov 18.
38. Kalita J, Shah S, Kapoor R, Misra UK. Bladder dysfunction in acute transverse myelitis: magnetic resonance imaging and neurophysiological and urodynamic correlations. J Neurol Neurosurg Psychiatry. 2002;73(2);154-159.
39. Krishnan C, Kaplin AI, Deshpande DM, et al. Transverse myelitis: clinical manifestations, pathogenesis, and management. In: Minagar A, Alexander JS, eds. Inflammatory Disorders of the Nervous System: Pathogenesis, Immunology, and Clinical Management. Totowa, NJ: Human Press Inc. 2005;218-219,221,237.
40. Krishnan C, Kaplin AI, Deshpande DM, et al. Transverse myelitis: pathogenesis, diagnosis, and treatment. Front Biosci. 2004;9:1483-1499.
41. Hauser SL, Asbury AK. Guillain-Barre syndrome and other immune-mediated neuropathies. In: Fauci AS, Braunwald E, Kasper DL, et al, eds. Harrison's Principles of Internal Medicine. 17th ed. Volumes I and II. New York: The McGraw-Hill Companies, Inc.; 2008:2667-2670.
42. Walshe III, Thomas M. Diseases of nerve and muscle. In: Samuels, MA, ed. Manual of Neurologic Therapeutics. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:429.
43. Raptiva (efalizumab) [package insert]. South San Francisco, CA: Genentech, Inc.
44. Shin IS, Baer AN, Kwon HJ, et al. Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum. 2006;54(5): 1429-1434.
45. Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain-Barré syndrome. Arch Neurol. 2001;58(6): 913-917.
46. Richez C, Blanco P, Lagueny A, et al. Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. Neurology. 2005;64(8):1468-1470.
47. Remicade (infliximab): Efficacy and Safety Review. Information for the Arthritis Advisory Committee. 2003 Mar 4. www.fda.gov/ohrms/dockets/ac/03/briefing/3930B1_04_A-Centocor-Remicade%20.pdf-2003-02-28. Accessed on October 28, 2009.